An observational study in Takayasu Arteritis With Pulmonary Artery Involvement and Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by China-Japan Friendship Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Connective Tissue Diseases with a site in China — 13 open to participants now, 18 under way, 7 of them phase 3. Connective Tissue Diseases · China.
Among the 27 studies in Connective Tissue Diseases with a site in China, this one is the only one that started in 2016, is one of 5 observational ones, reaches primary completion later than 11 of the 17 other live ones, and was the 27th registered.
192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.
Browse Connective Tissue Diseases studies →13 of the 27 studies in Connective Tissue Diseases with a site in China are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in China, United States, Argentina and 8 more countries
Ages 18+
GlaxoSmithKline · Sites in China, United States, Argentina and 15 more countries
Ages 18+
Tongji Hospital · Sites in China
Ages 18+
Beijing Hospital · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8 · Phase 4 6
First in 2014; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 180 across 55 observational studies indexed under Connective Tissue Diseases.
Median enrollment 224 across the 22 interventional studies, 150 across the 5 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 27 have an industry lead sponsor. The 10 most frequent:
China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.
China-Japan Friendship Hospital has 1 study filed under Connective Tissue Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Connective Tissue Diseases with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07184814China-Japan Friendship HospitalClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Connective Tissue Diseases with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).
The present study intends to conduct a prospective analysis of the clinical data in TAK patients in order to:
TAK patients hospitalized at the China-Japan Friendship Hospital, Beijing Anzhen Hospital and Beijing Chaoyang Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All-cause death
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.
Six-minute walk distance
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026
WHO functional class
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.
N-terminal pro-brain natriuretic peptide level
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026
Mean pulmonary arterial pressure assessed by right heart catheterization
Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.
Pulmonary vascular resistance assessed by right heart catheterization
Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.
Cardiac output assessed by right heart catheterization
Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.
Cardiac index assessed by right heart catheterization
Hemodynamic parameters assessed by right heart catheterization in patients with pulmonary hypertension.
Time frame: At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.
Started Jan 2016 (actual). Primary completion is estimated for Dec 2026, 131 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China-Japan Friendship Hospital →